Factor VIII Inhibitor Formation: Identifying Predisposing Genetic Factors
In collaboration with investigators of the Hemophilia Inhibitor Genetic Study (HIGS)
multicenter study and the University of Lund, University Hospital, Malmo, Sweden, we propose
to assess the role of genetic variants in the process of developing inhibitors to Factor
VIII in persons with hemophilia. The discovery of genetic associations offers the potential
to direct clinical management in order to prevent inhibitor development and improve clinical
care in patients with inhibitors.
Janelle Cortner, Ph.D.
National Cancer Institute (NCI)
United States: Federal Government